Liu Peifeng Adv Sci: New iron oxide nanoparticles inhibit tumor autophagy to treat liver cancer
QQ Academic Group: 1092348845

Detailed

The combination therapy of nanoparticles and autophagy inhibitors, such as chloroquine (CQ) and hydroxychloroquine (HCQ), has been extensively studied in tumor treatment. However, the toxicity and low selectivity of autophagy inhibitors seriously hinder the application of combination therapy. Liu Peifeng, Renji Hospital, Shanghai Jiaotong University School of Medicine, designed and identified a carboxyl functional iron oxide nanoparticle (Fe2O3@DMSA), which has a significant anti-tumor autophagy effect without adding CQ or HCQ. Further studies have shown that the effective inhibitory effect of Fe2O3@DMSA on the growth of liver cancer is triggered by inhibiting the fusion of autophagosomes and lysosomes to enhance anti-tumor autophagy. This fusion is induced by intracellular iron retention. Induced by continuous production of reactive oxygen species. In two tumor-bearing mouse models of liver cancer, Fe2O3@DMSA alone can effectively inhibit tumor growth without obvious side effects.



This article proves that Fe2O3@DMSA can inhibit tumor cell autophagy activation, so that it can play an anti-tumor autophagy cancer treatment effect without adding exogenous autophagy inhibitors. In addition, the anti-tumor autophagy effect of Fe2O3@DMSA not only overcomes the main challenge of non-selective distribution of autophagy inhibitors in the body, but also successfully avoids the serious side effects of autophagy chemical inhibitors. Therefore, this Fe2O3@DMSA anti-tumor strategy provides a potential cancer treatment strategy and is conducive to the development of iron oxide nanoparticles for biomedical applications.


This information is sourced from the Internet for academic exchanges. If there is any infringement, please contact us to delete it immediately
Scan the QR code to follow us Contact: 17319402180

Copyright © beijing beike new material Technology Co., Ltd 京ICP备16054715-2号